Monoclonal antibody therapies for aquaporin-4-immunoglobulin G-positive neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease.

Autor:	Tisavipat N; Department of Neurology, Mayo Clinic, Rochester, MN, United States., Juan HY; Virginia Commonwealth University School of Medicine, Richmond, VA, United States., Chen JJ; Department of Neurology, Mayo Clinic, Rochester, MN, United States.; Department of Ophthalmology, Mayo Clinic, Rochester, MN, United States.
Jazyk:	angličtina
Zdroj:	Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society [Saudi J Ophthalmol] 2023 Oct 24; Vol. 38 (1), pp. 2-12. Date of Electronic Publication: 2023 Oct 24 (Print Publication: 2024).
DOI:	10.4103/sjopt.sjopt_102_23
Abstrakt:	Monoclonal antibody therapies mark the new era of targeted treatment for relapse prevention in aquaporin-4 (AQP4)-immunoglobulin G (IgG)-positive neuromyelitis optica spectrum disorder (AQP4-IgG+NMOSD). For over a decade, rituximab, an anti-CD20 B-cell-depleting agent, had been the most effectiveness treatment for AQP4-IgG+NMOSD. Tocilizumab, an anti-interleukin-6 receptor, was also observed to be effective. In 2019, several randomized, placebo-controlled trials were completed that demonstrated the remarkable efficacy of eculizumab (anti-C5 complement inhibitor), inebilizumab (anti-CD19 B-cell-depleting agent), and satralizumab (anti-interleukin-6 receptor), leading to the Food and Drug Administration (FDA) approval of specific treatments for AQP4-IgG+NMOSD for the first time. Most recently, ravulizumab (anti-C5 complement inhibitor) was also shown to be highly efficacious in an open-label, external-controlled trial. Although only some patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) warrant immunotherapy, there is currently no FDA-approved treatment for relapse prevention in MOGAD. Observational studies showed that tocilizumab was associated with a decrease in relapses, whereas rituximab seemed to have less robust effectiveness in MOGAD compared to AQP4-IgG+NMOSD. Herein, we review the evidence on the efficacy and safety of each monoclonal antibody therapy used in AQP4-IgG+NMOSD and MOGAD, including special considerations in children and women of childbearing potential. Competing Interests: There are no conflicts of interest. (Copyright: © 2023 Saudi Journal of Ophthalmology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu